261 related articles for article (PubMed ID: 18521506)
1. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor.
Negaard HF; Iversen PO; Østenstad B; Iversen N; Holme PA; Sandset PM
Thromb Haemost; 2008 Jun; 99(6):1040-8. PubMed ID: 18521506
[TBL] [Abstract][Full Text] [Related]
2. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
Langer F; Chun FK; Amirkhosravi A; Friedrich M; Leuenroth S; Eifrig B; Bokemeyer C; Francis JL
Thromb Haemost; 2007 Mar; 97(3):464-70. PubMed ID: 17334515
[TBL] [Abstract][Full Text] [Related]
3. [Tissue factor (TF) and inhibitor (TFPI) concentrations in patients with urinary tract tumors and haematological malignancies].
Radziwon P; Schenk JF; Mazgajska K; Boczkowska-Radziwon B; Galar M; Kłoczko J; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Oct; 13(76):308-11. PubMed ID: 12557438
[TBL] [Abstract][Full Text] [Related]
4. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients.
Pawlak K; Mysliwiec M; Pawlak D
Thromb Haemost; 2009 Jul; 102(1):49-55. PubMed ID: 19572067
[TBL] [Abstract][Full Text] [Related]
5. A combined immunostimulatory and immunoinhibitory short interference RNA reduces hypercoagulability in a rat model of acute promyelocytic leukaemia.
Iversen PO; Sørensen DR; Sioud M
Thromb Haemost; 2010 Aug; 104(2):350-4. PubMed ID: 20539915
[TBL] [Abstract][Full Text] [Related]
6. Tumor M2-PK levels in haematological malignancies.
Oremek GM; Rox S; Mitrou P; Sapoutzis N; Sauer-Eppel H
Anticancer Res; 2003; 23(2A):1135-8. PubMed ID: 12820361
[TBL] [Abstract][Full Text] [Related]
7. Hemostasis activation in thrombophilic subjects with or without a history of venous thrombosis.
Cuderman TV; Bozic M; Peternel P; Stegnar M
Clin Appl Thromb Hemost; 2008 Jan; 14(1):55-62. PubMed ID: 17895509
[TBL] [Abstract][Full Text] [Related]
8. An experience with sixty cases of haematological malignancies; a clinico haematological correlation.
Idris M; Shah SH; Fareed J; Gul N
J Ayub Med Coll Abbottabad; 2004; 16(4):51-4. PubMed ID: 15762065
[TBL] [Abstract][Full Text] [Related]
9. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria.
Asero R; Tedeschi A; Coppola R; Griffini S; Paparella P; Riboldi P; Marzano AV; Fanoni D; Cugno M
J Allergy Clin Immunol; 2007 Mar; 119(3):705-10. PubMed ID: 17204316
[TBL] [Abstract][Full Text] [Related]
10. Hypercoagulation in chronic post-traumatic stress disorder.
Robicsek O; Makhoul B; Klein E; Brenner B; Sarig G
Isr Med Assoc J; 2011 Sep; 13(9):548-52. PubMed ID: 21991715
[TBL] [Abstract][Full Text] [Related]
11. Impact of neutrophil apoptosis on haemostatic activation in chronic liver disease patients.
Essawy FM; Bekheet IW; Saleh AF; Madkour ME; Bayoumi Eel-D
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):535-42. PubMed ID: 18685437
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism.
Kamikura Y; Wada H; Nobori T; Kobayashi T; Sase T; Nishikawa M; Ishikura K; Yamada N; Abe Y; Nishioka J; Nakano T; Shiku H
Thromb Res; 2005; 116(4):307-12. PubMed ID: 16038715
[TBL] [Abstract][Full Text] [Related]
13. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
[TBL] [Abstract][Full Text] [Related]
14. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
[TBL] [Abstract][Full Text] [Related]
15. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors.
Negaard HF; Iversen N; Bowitz-Lothe IM; Sandset PM; Steinsvik B; Ostenstad B; Iversen PO
Leukemia; 2009 Jan; 23(1):162-9. PubMed ID: 18800145
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis.
Sidelmann JJ; Bladbjerg EM; Gram J; Münster AM; Jespersen J
Blood Coagul Fibrinolysis; 2008 Jul; 19(5):405-9. PubMed ID: 18600090
[TBL] [Abstract][Full Text] [Related]
17. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation.
Langer F; Spath B; Haubold K; Holstein K; Marx G; Wierecky J; Brümmendorf TH; Dierlamm J; Bokemeyer C; Eifrig B
Ann Hematol; 2008 Jun; 87(6):451-7. PubMed ID: 18292996
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
Gheorghiade M; Thyssen A; Zolynas R; Nadar VK; Greenberg BH; Mehra M; Sun X; Tian H; Plotnikov AN; Burton P
J Heart Lung Transplant; 2011 Feb; 30(2):218-26. PubMed ID: 20947383
[TBL] [Abstract][Full Text] [Related]
19. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
Lizakowski S; Zdrojewski Z; Jagodzinski P; Rutkowski B
Scand J Urol Nephrol; 2007; 41(3):237-42. PubMed ID: 17469034
[TBL] [Abstract][Full Text] [Related]
20. The paradoxical association between inherited factor VII deficiency and venous thrombosis.
Marty S; Barro C; Chatelain B; Fimbel B; Tribout B; Reynaud J; Schved JF; Giansily-Blaizot M
Haemophilia; 2008 May; 14(3):564-70. PubMed ID: 18282149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
